Gsk (GSK) Acquisitions (2009 - 2026)

Gsk (GSK) has 15 years of Acquisitions data on file, last reported at -$2.8 billion in Q3 2026.

• For the quarter ending Q3 2026, Acquisitions changed N/A year-over-year to -$2.8 billion; the trailing twelve-month figure through Sep 2026 stood at -$6.8 billion (changed N/A YoY), and the FY2025 full-year result was -$2.3 billion, down 118.72% from the prior year.
• Acquisitions was -$2.8 billion for Q3 2026 at Gsk, down from -$1.9 billion in the prior quarter.
• In the past five years, Acquisitions ranged from a high of -$91.5 million in Q4 2022 to a low of -$2.8 billion in Q3 2026.
• A 5-year average of -$1.3 billion and a median of -$1.0 billion in 2025 frame the typical range for Acquisitions.
• Across the five-year window, Acquisitions plunged 1797.91% in 2023 and soared 44.71% in 2024, its largest moves.
• Gsk's Acquisitions stood at -$91.5 million in 2022, then plunged by 1797.91% to -$1.7 billion in 2023, then soared by 44.71% to -$960.1 million in 2024, then fell by 10.84% to -$1.1 billion in 2025, then plunged by 162.82% to -$2.8 billion in 2026.
• Per Business Quant data, the three most recent Acquisitions figures were -$2.8 billion in Q3 2026, -$1.9 billion in Q1 2026, and -$1.1 billion in Q4 2025.